Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 3/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20009051 | 0.81 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL26241700 | 0.80 | OPRM1 (0.47) | CHRNB2CHRNB4CHRNA3CHRNA4OPRM1 | |
| SCHEMBL20009027 | 0.80 | CYP11B2 (0.35) | CHRNB2CHRNB4CHRNA3CHRNA4OPRM1 | |
| SCHEMBL20009008 | 0.77 | HRH3 (0.35) | HRH3OPRM1 | |
| SCHEMBL20008965 | 0.75 | OPRM1 (0.47) | HRH3OPRM1 | |
| SCHEMBL20009020 | 0.72 | DRD3 (0.39) | HRH3OPRM1 | |
| SCHEMBL20009044 | 0.72 | KDM4E (0.37) | PDE9A | |
| SCHEMBL15907020 | 0.72 | PDE9A (0.40) | HRH3PDE9A | |
| SCHEMBL22794068 | 0.71 | OGA (0.33) | HRH3PDE9A | |
| SCHEMBL20012877 | 0.71 | OPRM1 (0.46) | CHRNB2CHRNB4CHRNA3CHRNA4OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | CHRNB2 1123/4885CHRNB4 1088/4885CHRNA3 1158/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | CHRNB2 1123/4885CHRNB4 1088/4885CHRNA3 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.